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VIEWPOINT

A potential mechanism for extracellular matrix
induction of breast cancer cell normality
Robert D Bruno1 and Gilbert H Smith2*
Abstract
Extracellular matrix proteins from embryonic
mesenchyme have a normalizing effect on cancer
cells in vitro and slow tumor growth in vivo. This
concept is suggestive of a new method for controlling
the growth and spread of existing cancer cells in situ
and indicates the possibility that extracellular proteins
and/or embryonic mesenchymal fibroblasts may
represent a fertile subject for study of new anti-cancer
treatments.
Bischof and colleagues have made a case for breast cancer cell normalization by biglycan isolated from embryonic mesenchyme in vitro [1]. Further, they show that
injection of extracellular matrix (ECM) isolated from
embryonic mesenchymal fibroblasts grown in vitro can
suppress tumor growth when inoculated directly into
growing tumors in vivo. Their results shed light on the
potential mechanism by which embryonic mesenchyme
can control tumorigenic expression of cancer cells,
which was demonstrated by several investigators decades
ago [2,3]. The evidence indicates that only ECM from
inductive mesenchyme is effective in normalization of
cancer cells. In Bischof and colleagues’ report, cancerassociated fibroblasts failed to produce a normalizing
effect. The authors went on to show that tenascin C and
biglycan were two ECM proteins that were uniquely
expressed by inductive embryonic mesenchymal fibroblasts. Further, they demonstrated that only biglycan was
able to normalize cancer cells in vitro. Isolated growth
factors associated tightly with the purified ECM were
ineffective in normalizing breast cancer cells. Finally,
siRNA knockdown of biglycan mRNA and protein in embryonic fibroblasts abrogated their ability to normalize
breast cancer cells or reduce their growth in vitro.
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Biglycan has been disrupted by targeting in mice, and
variously leads to an osteoporosis-like phenotype and biomechanically affected specific tendons [4-6]. One wonders
how the embryonic mesenchyme from these models
might behave in normalization studies.
While the implication of a single ECM component,
biglycan, is intriguing from a therapeutic perspective,
this reductionist view of the role of ECM in controlling
tumorigenesis is not in agreement with the published literature. Schedin and colleagues have very carefully studied the role of mammary ECM in breast tumorigenesis
[7-10]. They have found that reproductive history and
the developmental state of the gland from which the
breast ECM was isolated alters the effects of the ECM
on tumor growth. For instance, ECM derived from involuting mammary tissues has pro-tumor effects compared
with that isolated from nulliparous tissues, and this protumorigenic potential is thwarted by treatment with
nonsteroidal anti-inflammatory drugs [8,9]. In addition,
they report that ECM isolated from parous mammary
glands has an inhibitory effect on tumor growth [7].
Contrary to Bischof and colleagues’ findings that biglycan is uniquely expressed in inductive mesenchyme,
biglycan was found to be present in ECM preparations
from nulliparous, parous, and involuting (with or without prior nonsteroidal anti-inflammatory drug treatment) rat mammary glands. Further, no significant
differences in biglycan concentrations were identified
between these ECM preparations [7,10].
Our laboratory has also been interested in trying to
understand tissue-microenvironment-induced suppression of cancer cell tumorigenesis. Our data demonstrate
that pluripotent human male cancer cells, mouse embryonic stem cells and breast cancer cells from both mouse
and human can be induced to differentiate and not
produce tumors in the mouse mammary gland during
regenerative growth [11-14]. All of our published data
have been determined in postpubertal mammary fat
pads whose mesenchyme, according to Sakakura and
colleagues [15], had lost inductive activity after interaction
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with mammary epithelium in utero at day 17. Thus, our
observations and those of Schedin and colleagues do
not agree with the conclusion of Bischof and colleagues
that biglycan is sufficient for tumor cell normalization
and that tumor cell normalization is unique to inductive
mesenchyme.
The specific components involved in tumor-cell
normalization are likely to be context dependent. Furthermore, changes in ECM architecture rather than ECM
composition are implicated in tumor suppression by ECM
isolated from mammary glands of parous rats [7], adding
an additional layer of complexity to the story. Therefore,
reductionist approaches to understanding these issues
should be cautioned. What is clear from the whole of the
published literature, including the recent report by Bischof
and colleagues, is the indispensable role of the local
microenvironment, including the ECM, in controlling cell
growth, survival, and fate determination.
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